A hypoxia-responsive supramolecular formulation for imaging-guided photothermal therapy

Zhang, Tian-Xing; Hou, Xiaoxue; Kong, Yong; Yang, Fan; Yue, Yu‐Xin; Shah, Muhammad Raza; Li, Hua-Bin; Huang, Fan; Liu, Jianfeng; Guo, Dong‐Sheng

doi:10.7150/thno.67036

Cited by 44 publications

(29 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 7c ] The broad recognition capability of SAC4A promises it as a modular platform capable of delivering other anti‐inflammatory drugs. [ 33 ] We, therefore, evaluated the binding affinities of SAC4A with another four anti‐inflammatory drugs (Figures S30–S33, Supporting Information) widely used in clinic, such as triamcinolone acetonide acetate ((3.8 ± 0.9) × 10 6 m −1 ), dexamethasone ((3.3 ± 0.3) × 10 5 m −1 ), DASA‐58 ((6.0 ± 0.5) × 10 5 m −1 ), and rosiglitazone hydrochloride ((4.2 ± 0.8) × 10 5 m −1 ). Strong binding to these drugs is a prerequisite to reduce the premature dissociation of the complexes when applied to organisms.…”

Section: Resultsmentioning

confidence: 99%

Drug in Drug: A Host–Guest Formulation of Azocalixarene with Hydroxychloroquine for Synergistic Anti‐Inflammation

et al. 2022

Advanced Materials

View full text Add to dashboard Cite

Macrocyclic delivery and therapeutics are two significant topics in supramolecular biomedicine. The functional integration of these topics would open new avenues for treating diseases synergistically. However, these two individual topics have only been occasionally merged, probably because of the lack of functionalized design of macrocyclic host and the lack of efficient recognition between host and guest drugs. Herein, a “drug‐in‐drug” strategy is proposed, in which an active drug is encapsulated by a macrocycle possessing therapeutic activity to form a multifunctional supramolecular active pharmaceutical ingredient. As a proof‐of‐concept, a complex of hydroxychloroquine (HCQ) with sulfonated azocalix[4]arene (HCQ@SAC4A) is prepared to treat rheumatoid arthritis (RA) in a combined fashion. SAC4A is a therapeutic agent that exhibits scavenging capacity for reactive oxygen species and exerts an anti‐inflammatory effect. It is also a hypoxia‐responsive carrier that can deliver HCQ directly to the inflammatory articular cavity. Consequently, HCQ@SAC4A achieves the synergistic anti‐inflammatory effect on both inflamed RAW 264.7 cells and RA rats. This effect is attributed to the temporal and spatial consistency of the two active ingredients of the complex. As a new paradigm for combinational therapy, the drug‐in‐drug strategy advances in easy preparation, mix‐and‐match combination, and precise ratiometric control.

show abstract

Section: Resultsmentioning

confidence: 99%

Drug in Drug: A Host–Guest Formulation of Azocalixarene with Hydroxychloroquine for Synergistic Anti‐Inflammation

et al. 2022

Advanced Materials

View full text Add to dashboard Cite

show abstract

“…Recently, Guo et al reported a supramolecular formulation of a hypoxia-responsive calixarene derivative and an IR780 dye for effective imaging-guided PTT. 26 Due to the unique architecture and chemical modification possibilities, calixarene macrocycles have received a lot of attention from the scientific community as agents for coating of AuNPs. The combination with the calixarene skeleton can endow AuNPs with new physicochemical and optical properties crucial for applications ranging from sensing 27,28 to cancer diagnosis and therapy.…”

Section: ■ Introductionmentioning

confidence: 99%

Near-Infrared-Responsive Choline-Calix[4]arene-Gold Nanostructures for Potential Photothermal Cancer Treatment

Consoli¹,

Forte

Maugeri

et al. 2022

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

The development of novel chemical approaches for the fabrication of gold nanostructures with localized surface plasmon resonance (LSPR) falling in the near-infrared (NIR) region is one challenging topic in nanomaterials science. Due to their optical and photothermal properties triggered by light excitation in the therapeutic window (λ max = 650−1300 nm), gold-based nanostructures are appealing candidates in anticancer nanomedicine. Here, we report a novel method to prepare waterdispersible gold nanostructures with NIR-LSPR (λ max = 600−1000 nm) properties. The gold nanostructures were achieved in a single step by an unconventional method using NADH as a reducing agent and an amphiphilic choline-calix[4]arene derivative (Chol-Calix) forming micelles as a template. The CholCalix-Au nanostructures were characterized by UV−visible spectrophotometry, Raman spectroscopy, and atomic force microscopy. Agglomeration of the nanostructures due to multiple crosslinking interactions was observed and supported by modeling simulation. Effective anticancer photothermal-induced effect of the CholCalix-AuNPs was demonstrated on human breast cancer cells irradiated with biofriendly light at 808 nm.

show abstract

“…Normal saline was purchased from Rhawn. SC5A, [ 36 ] SAC4A [ 37 ] and carboxylated azocalix[ n ]arenes (CAC n As, n = 4, 5, 6, 8) [ 38 ] were synthesized and purified according to literature procedures.…”

Section: Methodsmentioning

confidence: 99%

Promoting Tumor Accumulation of Anticancer Drugs by Hierarchical Carrying of Exogenous and Endogenous Vehicles

et al. 2022

Self Cite

View full text Add to dashboard Cite

Cancer is still a major public health problem and a leading cause of death worldwide. [1] Currently, an increasing number of emerging therapeutic modalities, such as immunotherapy, gene therapy, photodynamic therapy, photothermal therapy, and chemodynamic therapy, have been developed in addition to traditional surgery, radiation, and chemotherapy. [2] In all drug treatments, the tumor accumulation of active pharmaceutical ingredients is a crucial parameter, as it is essential for the concentration of the drug to reach its therapeutic threshold rapidly to produce an effective response. [3] Numerous anticancer formulations have been widely studied and put into clinical practice to improve the tumor accumulation of drugs. Smallmolecular prodrugs are derivatives of active drugs, [4] which undergo biotransformation to release the parent drug by exploiting specific hallmarks of tumor microenvironments (e.g., pH, enzyme expression, reactive oxygen species) or by utilizing external triggers (e.g., light, ultrasound, magnetic energy). [5] Moreover, targeted drugs refer to a new generation of anticancer drugs designed to interfere with a specific molecular target (typically a protein), anticipated to have a critical role in tumor growth or progression. [6] To promote tumor accumulation, targeted drugs have gained importance, including small molecules (e.g., tyrosine kinase, mammalian target of rapamycin and proteasome inhibitors) and macromolecules (e.g., monoclonal antibodies, polypeptides, antibody-drug conjugates, and nucleic acids). [7] In recent decades, nanomedicine has gained ever-growing attention in fighting cancer. [8] Nanomedicine provides an alternate pathway to improve tumor accumulation relying on a wide range of targeting strategies such as active targeting, passive targeting (enhanced permeation and retention [EPR] effect), stimuliresponsive targeting and their combination. [9] Despite these significant achievements, the drawbacks of high tumor accumulation have not yet been addressed well. [3,10] Currently, only a few formulations (e.g., Abraxane, Lapatinib, Telotristat etiprate) (www.clinicaltrials.gov) have been clinically approved to modify the toxicological profile of drugs in patients. [11]

show abstract

A hypoxia-responsive supramolecular formulation for imaging-guided photothermal therapy

Cited by 44 publications

References 67 publications

Drug in Drug: A Host–Guest Formulation of Azocalixarene with Hydroxychloroquine for Synergistic Anti‐Inflammation

Drug in Drug: A Host–Guest Formulation of Azocalixarene with Hydroxychloroquine for Synergistic Anti‐Inflammation

Near-Infrared-Responsive Choline-Calix[4]arene-Gold Nanostructures for Potential Photothermal Cancer Treatment

Promoting Tumor Accumulation of Anticancer Drugs by Hierarchical Carrying of Exogenous and Endogenous Vehicles

Contact Info

Product

Resources

About